Author:
Thomas M B,Koller C,Yang Y,Shen Y,O'Brien S,Kantarjian H,Davis J,Estey E
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference8 articles.
1. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ . Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 1993; 9(4–5): 343–350.
2. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9(6): 965–971.
3. Visani G, Tosi P, Zinzani PL, Manfroi S, Zaccaria A, Testoni N et al. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. Br J Haematol 1994; 86(2): 394–396.
4. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58(2): 105–109.
5. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99(4): 939–944.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献